[Immunosuppressive therapy for inflammatory bowel disease: consensus by the Austrian working group on IBD].
Reinisch
W
W
Univ.-Klinik f. Innere Medizin IV, Abteilung Gastroenterologie und Hepatologie, AKH Wien, Austria.
Dejaco
C
C
Knoflach
P
P
Petritsch
W
W
Vogelsang
H
H
Tilg
H
H
D000284:Administration, Oral; D001379:Azathioprine / Q000008:administration & dosage / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy; D003424:Crohn Disease / Q000188:drug therapy; D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D007273:Injections, Intramuscular; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage / Q000627:therapeutic use; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D010919:Placebos; D011247:Pregnancy; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D012189:Retrospective Studies; D012449:Safety; D013997:Time Factors
D007166:Immunosuppressive Agents; D010919:Placebos; D016572:Cyclosporine; D015122:Mercaptopurine; D001379:Azathioprine; D008727:Methotrexate
Immunsuppressiva in der Therapie chronisch entzündlicher Darmerkrankungen. Konsensus der Arbeitsgruppe Chronisch Entzündliche Darmerkrankungen der OGGH.